e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Translational studies in chronic lung diseases: from bedside to bench
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
E. Papakonstantinou, M. Roth, G. Karakiulakis, S. Savic, M. Tamm, D. Stolz (Thessaloniki, Greece; Basel, Switzerland)
Source:
Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Session:
Translational studies in chronic lung diseases: from bedside to bench
Session type:
Poster Discussion
Number:
259
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Papakonstantinou, M. Roth, G. Karakiulakis, S. Savic, M. Tamm, D. Stolz (Thessaloniki, Greece; Basel, Switzerland). Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation. Eur Respir J 2013; 42: Suppl. 57, 259
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Source: International Congress 2016 – Inflammatory biomarkers in airway diseases
Year: 2016
Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013
Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
COPD exacerbation severity is associated with impaired macrophage phagocytosis of eosinophils
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Altered inflammasome activity in bacterial acute exacerbations of COPD (AECOPD)
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Inflammation biomarkers of lung tissue damage in acute exacerbation of COPD patients
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation
Source: International Congress 2014 – Markers
Year: 2014
IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Inflammatory serum profiles are consistent across independent exacerbations in COPD patients with a history of frequent exacerbations
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Relationship of blood eosinophil count to exacerbations in COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016
Serum periostin in patients hospitalized for COPD exacerbations
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
MUC1-CT mediates corticosteroid responses in COPD
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU
Year: 2013
Recruitment of blood fibrocytes during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4 dependent pathway
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept